关键词: 晚期胃癌, 免疫治疗

Abstract: Advances on immunotherapy for late-stage gastric cancer        ZHOU Zhi-jun*, XU Yan, JIN Fang, et al. *The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Corresponding authors：PENG Jian-jun，E-mail:pjianj@mail.sysu.edu.cn；ZHANG Chang-hua，E-mail:zhchangh@mail.sysu.edu.cn
ZHOU Zhi-jun and XU Yan are the first authors who contributed equally to the article. 
Abstract    Patients with late-stage gastric cancer lost the opportunity of radical resection at the time of diagnosis. For these patients, treatment options are limited. Traditional treatment is mainly chemotherapy in combination with targeted therapy. Nonetheless, the prognosis of these patients is dismal. The emerging immunotherapy in recent years, especially immune checkpoint inhibitors ( ICIs) , showed an impressive responses in a subset of patients, and even brought long-term survival for some patients. Immunotherapy showed better treatment outcomes than traditional therapies such as first-line and multiple-line treatment for late-stage gastric cancer. Recently, several phase 3 multicenter randomized clinical trials showed promising results of immunotherapy in late-stage gastric cancer, which has shifted the treatment paradigm of gastric cancer. The development of novel immunotherapy strategies will further improve the treatment outcomes for these patients. 

Key words: late-stage gastric cancer, immunotherapy